Logo

Correlogic and Japanese Mass Spec Maker to Improve Clinical Mass Spectrometry

Jun 06, 2007
NEW YORK (GenomeWeb News) — Correlogic Systems has signed a research and development agreement with a Japanese mass-spec maker to enhance clinical mass spectrometry, Correlogic said today.
 
Correlogic and Tokyo-based JEOL, which also makes nuclear magnetic resonance instruments and electron optical equipment, have been involved in an “informal” research collaboration for more than a year, Correlogic said. The firm said they have “made great strides in the continuing validation of various mass spectrometer-based assays.”
 
Financial details of the agreement were not disclosed.

Filed under

Proteomics & Protein Research
proteomics
Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.